Related Experiment Video

Updated: Oct 27, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.8K

Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer

Huayi Li1, Lorenzo Prever1, Emilio Hirsch1

  • 1Department of Molecular Biotechnology and Health Sciences, University of Turin, 10126 Turin, Italy.

Cancers
|July 24, 2021
PubMed

Insights

Effective breast cancer treatments are needed to prevent metastasis. This review focuses on the PI3K signaling pathway and new PI3K-targeting therapies for breast cancer, highlighting the need for sophisticated strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Breast cancer is a leading cause of cancer death in women globally.
  • While survival rates have improved, effective systemic treatments to prevent metastasis are still needed.
  • The PI3K/AKT/mTOR pathway is frequently altered in breast cancer, driving cell growth, survival, and motility.

Purpose of the Study:

  • To review the role of the PI3K signaling pathway in breast cancer.
  • To discuss the most recent PI3K-targeting therapies for breast cancer.
  • To highlight the need for specific and sophisticated therapeutic strategies.

Main Methods:

  • Literature review of PI3K signaling in breast cancer.
  • Analysis of preclinical studies on PI3K inhibitors.
  • Discussion of recent advancements in PI3K-targeting breast cancer therapies.

Main Results:

  • The PI3K/AKT/mTOR pathway is a critical regulator of breast cancer progression.
  • Numerous PI3K inhibitors have shown promise in preclinical studies.
  • The diverse roles of PI3K signaling necessitate tailored therapeutic approaches.

Conclusions:

  • Targeting the PI3K pathway is a promising strategy for breast cancer treatment.
  • Developing specific and sophisticated PI3K inhibitors is crucial for effective therapy.
  • Further research is needed to optimize PI3K-targeting strategies to prevent metastasis.
Keywords:
AKTPI3Kbreast cancerclass II PI3Kclinical trialinhibitormTORmetastasis

More Related Videos

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

1.4K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.2K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.7K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.1K